Learn more about Compounded Semaglutide Injection Will fasting while taking semaglutide or tirzepatide cause muscle loss
Licensed provider reviews and determines eligibility
Pinto LC, Rados DV, Remonti LR, Kramer CK, Leitao CB, Gross JL
Safety Profile The most common adverse events documented across retatrutide results data were gastrointestinal in nature, with incidence increasing at higher doses: Nausea: 6-31% (dose-dependent), primarily during escalation periods Diarrhea: 6-25%, generally mild to moderate Vomiting: 0-16%, occurring mainly in the first weeks of each dose increase Decreased appetite: 3-19%, which contributed to the weight reduction effect Constipation: 3-12%, consistent with GLP-1 receptor-mediated gastric slowing Serious adverse events were rare across all cohorts
The category is expanding